166 related articles for article (PubMed ID: 31028097)
1. Loss of Notch1 Activity Inhibits Prostate Cancer Growth and Metastasis and Sensitizes Prostate Cancer Cells to Antiandrogen Therapies.
Rice MA; Hsu EC; Aslan M; Ghoochani A; Su A; Stoyanova T
Mol Cancer Ther; 2019 Jul; 18(7):1230-1242. PubMed ID: 31028097
[TBL] [Abstract][Full Text] [Related]
2. Antiandrogen abiraterone and docetaxel treatments affect Notch1, Jagged1 and Hes1 expressions in metastatic prostate cancer cells.
Soylu H; Kırca M; Avcı S; Ozpolat B; Ustunel I
Exp Mol Pathol; 2021 Apr; 119():104607. PubMed ID: 33482170
[TBL] [Abstract][Full Text] [Related]
3. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer.
Stoyanova T; Riedinger M; Lin S; Faltermeier CM; Smith BA; Zhang KX; Going CC; Goldstein AS; Lee JK; Drake JM; Rice MA; Hsu EC; Nowroozizadeh B; Castor B; Orellana SY; Blum SM; Cheng D; Pienta KJ; Reiter RE; Pitteri SJ; Huang J; Witte ON
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6457-E6466. PubMed ID: 27694579
[TBL] [Abstract][Full Text] [Related]
4. Systematic Evaluation for the Influences of the SOX17/Notch Receptor Family Members on Reversing Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells.
Du Z; Li L; Sun W; Zhu P; Cheng S; Yang X; Luo C; Yu X; Wu X
Front Oncol; 2021; 11():607291. PubMed ID: 33791203
[TBL] [Abstract][Full Text] [Related]
5. Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer.
Rice MA; Malhotra SV; Stoyanova T
Front Oncol; 2019; 9():801. PubMed ID: 31555580
[TBL] [Abstract][Full Text] [Related]
6. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
7. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.
Moilanen AM; Riikonen R; Oksala R; Ravanti L; Aho E; Wohlfahrt G; Nykänen PS; Törmäkangas OP; Palvimo JJ; Kallio PJ
Sci Rep; 2015 Jul; 5():12007. PubMed ID: 26137992
[TBL] [Abstract][Full Text] [Related]
8. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
Crawford ED; Schellhammer PF; McLeod DG; Moul JW; Higano CS; Shore N; Denis L; Iversen P; Eisenberger MA; Labrie F
J Urol; 2018 Nov; 200(5):956-966. PubMed ID: 29730201
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis.
Liu X; Luo X; Wu Y; Xia D; Chen W; Fang Z; Deng J; Hao Y; Yang X; Zhang T; Zhou L; Wu Y; Wang Q; Xu J; Hu X; Li L
Cell Physiol Biochem; 2018; 50(1):261-276. PubMed ID: 30282072
[TBL] [Abstract][Full Text] [Related]
10. Targeted Notch1 inhibition with a Notch1 antibody, OMP-A2G1, decreases tumor growth in two murine models of prostate cancer in association with differing patterns of DNA damage response gene expression.
Ahmed AA; Robinson T; Palande M; Escara-Wilke J; Dai J; Keller ET
J Cell Biochem; 2019 Oct; 120(10):16946-16955. PubMed ID: 31099068
[TBL] [Abstract][Full Text] [Related]
11. Rational Second-Generation Antiandrogen Use in Prostate Cancer.
Orme JJ; Pagliaro LC; Quevedo JF; Park SS; Costello BA
Oncologist; 2022 Mar; 27(2):110-124. PubMed ID: 35641216
[TBL] [Abstract][Full Text] [Related]
12. Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer.
Martin SK; Pu H; Penticuff JC; Cao Z; Horbinski C; Kyprianou N
Cancer Res; 2016 Feb; 76(4):912-26. PubMed ID: 26645563
[TBL] [Abstract][Full Text] [Related]
13. Safety of antiandrogen therapy for treating prostate cancer.
Ricci F; Buzzatti G; Rubagotti A; Boccardo F
Expert Opin Drug Saf; 2014 Nov; 13(11):1483-99. PubMed ID: 25270521
[TBL] [Abstract][Full Text] [Related]
14. Recent trends in the management of advanced prostate cancer.
Ritch C; Cookson M
F1000Res; 2018; 7():. PubMed ID: 30345007
[TBL] [Abstract][Full Text] [Related]
15. Abiraterone acetate in castration-resistant prostate cancer.
Iacovelli R; Palazzo A; Procopio G; Gazzaniga P; Cortesi E
Anticancer Drugs; 2012 Mar; 23(3):247-54. PubMed ID: 22123334
[TBL] [Abstract][Full Text] [Related]
16. P450-dependent enzymes as targets for prostate cancer therapy.
De Coster R; Wouters W; Bruynseels J
J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):133-43. PubMed ID: 8603034
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor α-NOTCH1 axis enhances basal stem-like cells and epithelial-mesenchymal transition phenotypes in prostate cancer.
Shen Y; Cao J; Liang Z; Lin Q; Wang J; Yang X; Zhang R; Zong J; Du X; Peng Y; Zhang J; Shi J
Cell Commun Signal; 2019 May; 17(1):50. PubMed ID: 31122254
[TBL] [Abstract][Full Text] [Related]
18. Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer.
Zhang Y; Castaneda S; Dumble M; Wang M; Mileski M; Qu Z; Kim S; Shi V; Kraft P; Gao Y; Pak J; Sapra P; Bandaru R; Zhao H; Vessella RL; Horak ID; Greenberger LM
Mol Cancer Ther; 2011 Dec; 10(12):2309-19. PubMed ID: 22027692
[TBL] [Abstract][Full Text] [Related]
19. Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer.
Leone G; Tucci M; Buttigliero C; Zichi C; Pignataro D; Bironzo P; Vignani F; Scagliotti GV; Di Maio M
Endocr Relat Cancer; 2018 Jan; 25(1):R1-R9. PubMed ID: 28971898
[TBL] [Abstract][Full Text] [Related]
20. Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy.
Narayanan S; Srinivas S; Feldman D
Nat Rev Urol; 2016 Jan; 13(1):47-60. PubMed ID: 26643568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
